- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic rhinosinusitis with nasal polyps (CRSwNP)
- Meeting Date: May 2025
- Public Summary Document (PSD) May 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) May 2025 PBAC Meeting - (Word)
Omalizumab – May 2025
Omalizumab: Injection 75 mg in 0.5 mL single dose pre-filled syringe, Injection 150 mg in 1 mL single dose pre-filled syringe, Injection 300 mg in 2 mL single dose pre-filled syringe, Injection 75 mg in 0.5 mL single dose pre-filled pen, , Injection 150 mg in 1 mL single dose pre-filled pen, Injection 300 mg in 2 mL single dose pre-filled pen; Xolair®
Last updated
9 May 2025
